Key facts
- Onya Therapeutics’s last known valuation is $3.1M (Jan 2025).
- It has raised $6.4M.
- Notable investors include Baker Tilly Ireland Audit, Bionexus, CTL Engineering (electrical equipment), Neem Biotech, South East Angels — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Onya Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Onya Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Onya Therapeutics
Developer of a medicated patch designed to transform passive wound care into active wound healing. The company offers a patented patch with targeted therapeutic delivery, enabling patients with chronic and acute wounds to experience improved healing outcomes and reduced care burden.
- Sector
- Healthcare
- HQ
- Ebbw Vale, United Kingdom
- Founded
- 2020
- Employees
- 10
- Website
- onya.bio/
- Ownership
- Privately Held (backing)
Onya Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Onya Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Onya Therapeutics in its N-PORT filings yet. We sweep new filings monthly.